Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7874382 | 0.87 | — | — | |
| SCHEMBL32688488 | 0.85 | EPHX2 (0.36) | EPHX2KDM4ELMNAGAAALDH1A1 | |
| SCHEMBL1089533 | 0.85 | EPHX2 (0.36) | EPHX2KDM4ELMNAALDH1A1 | |
| SCHEMBL2961193 | 0.82 | NAAA (0.41) | EPHX2 | |
| SCHEMBL7062726 | 0.81 | NAAA (0.46) | EPHX2LMNA | |
| SCHEMBL1087620 | 0.81 | EPHX2 (0.41) | EPHX2KDM4ELMNAGAAALDH1A1 | |
| SCHEMBL5053685 | 0.78 | EPHX2 (0.36) | EPHX2KDM4ELMNAGAAALDH1A1 | |
| SCHEMBL32689094 | 0.78 | EPHX2 (0.40) | EPHX2KDM4ELMNAGAAALDH1A1 | |
| SCHEMBL14449006 | 0.77 | KDM4E (0.47) | EPHX2KDM4ELMNAGAAALDH1A1 | |
| SCHEMBL4402348 | 0.77 | KDM4E (0.47) | EPHX2KDM4ELMNAGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113045413-A | Method for preparing single-configuration C-2-position monosubstituted norbornene derivative | 合肥工业大学 | 2021-06-29 | — | — | CN | claimed |
| US-7901867-B2 | Sulphonium salt initiators | BASF SE (DE) | 2011-03-08 | — | — | US | disclosed |
| EP-1902019-B1 | SULPHONIUM SALT INITIATORS | BASF SE (DE) | 2010-07-07 | — | — | EP | disclosed |
| US-20090208872-A1 | Sulphonium Salt Initiators | BASF SE (DE) | 2009-08-20 | — | — | US | disclosed |
| US-20010036591-A1 | Iodonium salts as latent acid donors | IGM GROUP B.V. (NL) | 2001-11-01 | — | — | US | disclosed |
| US-6306555-B1 | RADIATION-SENSITIVE COMPOSITION COMPRISING CATIONICALLY OR ACID-CATALYTICALLY POLYMERISABLE OR CROSSLINKABLE COMPOUND OR COMPOUND THAT INCREASES ITS SOLUBILITY IN DEVELOPER UNDER ACTION OF ACID, AND AT LEAST ONE DIARYLIODONIUM SALT | CIBA SPECIALTY CHEMICALS CORP. | 2001-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090208872-A1 | Sulphonium Salt Initiators | OR10J3, OXSR1, ARSA | EPHX2 2392/4885KDM4E 3536/4885LMNA 2184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.